Surgical Science Sweden AB (publ) (SUS) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Surgical Science Q2 Report 2025 presentation. During the Q&A session, participants can ask questions by pressing pound key 5 on their telephone keypad. During the Q&A, we kindly ask participants to limit themselves to two questions at first. If you have additional questions, please queue up again by pressing pound key 5. Now, I will hand over to the speakers, CEO Tom Englund and CFO Anna Ahlberg. Please go ahead. Hi everyone and welcome to this Q2 presentation for Surgical Science. My name is Tom Englund, CEO of Surgical Science and with me today I have Anna Ahlberg, our company CFO. We will use our time together today to first present the report and then we will take questions from the audience. Despite a strong Q1 and start of the year, we saw more negative financial development during the second quarter. primarily driven by a weaker macroeconomic climate in some of our key markets. Sales was 209 million SEC, or 2% decrease versus the same quarter last year. Sales grew by 4%, however, in local currencies. The quarter also saw a significant impact from currency effects, affecting the result negatively by around 24 million SEC. Despite the financial headwinds during the quarter, our company maintained a high execution pace and achieved several important milestones, many of which will have positive impact already in the next few quarters. I want to present the most important highlights and results of the business during the quarter. After a good start of the year for educational products with a 32% increase in sales in the first quarter, our second quarter was significantly weaker with a 12% contraction in sales, both for comparable units excluding intelligent ultrasound. A large part of the contraction came from the US due to continued pressure on procurem...